List of Excipients in Branded Drug NICARDIPINE HYDROCHLORIDE IN SODIUM CHLORIDE

Generic Drugs Containing NICARDIPINE HYDROCHLORIDE IN SODIUM CHLORIDE

Company	Ingredient	NDC	Excipient
WG Critical Care LLC	nicardipine hydrochloride	44567-850	ANHYDROUS CITRIC ACID
WG Critical Care LLC	nicardipine hydrochloride	44567-850	SODIUM CHLORIDE
WG Critical Care LLC	nicardipine hydrochloride	44567-850	SODIUM HYDROXIDE
WG Critical Care LLC	nicardipine hydrochloride	44567-850	SORBITOL

What are the Most Frequently-Used Excipients in NICARDIPINE HYDROCHLORIDE IN SODIUM CHLORIDE?

# Of NDCs	Excipient
1	ANHYDROUS CITRIC ACID
1	SODIUM CHLORIDE
1	SODIUM HYDROXIDE
1	SORBITOL

Nicardipine Hydrochloride in Sodium Chloride: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 9, 2026

Nicardipine hydrochloride in sodium chloride is an established intravenous calcium-channel blocker product used for rapid blood-pressure control in critical-care settings. The commercial opportunity is concentrated in ready-to-use premixed bags, supply reliability, container-closure performance, and hospital workflow rather than in new-molecule exclusivity. The active ingredient is long off-patent, while regulatory differentiation can arise from concentration, presentation, stability, manufacturing controls, and compatibility data.

What is nicardipine hydrochloride in sodium chloride?

Nicardipine hydrochloride is a dihydropyridine calcium-channel blocker administered by continuous intravenous infusion when rapid and titratable blood-pressure reduction is required. The sodium chloride presentation is a ready-to-use infusion solution containing nicardipine hydrochloride in 0.9% sodium chloride, generally at a low concentration suitable for controlled infusion.

FDA labeling identifies nicardipine hydrochloride injection as an intravenous product for short-term treatment of hypertension when oral therapy is not feasible or desirable. The drug is titrated according to blood-pressure response and is administered through an infusion pump. [1]

The principal product attributes are:

Attribute	Commercial relevance
Active ingredient	Nicardipine hydrochloride
Pharmacologic class	Dihydropyridine calcium-channel blocker
Route	Intravenous infusion
Typical clinical setting	ICU, perioperative care, emergency hypertension, neurologic blood-pressure management
Vehicle	Sodium chloride solution
Dosage form	Sterile ready-to-use infusion solution or concentrate requiring dilution
Regulatory pathway	ANDA for equivalent generic product; 505(b)(2) may apply to materially different presentations
Biosimilar exposure	None; nicardipine is a small molecule
Main competitive factors	Availability, bag size, concentration, stability, compatibility, price, and hospital contracting

What excipients are used in nicardipine hydrochloride in sodium chloride?

The core excipient system is deliberately simple. Sodium chloride provides the infusion vehicle and helps establish an appropriate tonicity. Hydrochloric acid or sodium hydroxide may be used for pH adjustment, depending on the formulation and manufacturing process. Product labels should be reviewed for the exact inactive-ingredient declaration because formulations and presentations can vary by manufacturer. [1,2]

Excipient function and formulation role

Excipient or component	Primary function	Key development issue
Sodium chloride	Vehicle and tonicity agent	Osmolality, precipitation risk, and infusion tolerability
Hydrochloric acid	pH adjustment	Chemical stability and chloride balance
Sodium hydroxide	pH adjustment	pH control and product consistency
Water for Injection	Solvent	Sterility, endotoxin, and particulate control
Container material	Not an excipient, but formulation-critical	Adsorption, leachables, permeability, and extractables

The most important formulation variable is pH. Nicardipine hydrochloride solutions are acidic, and pH control affects solubility, degradation, color, particulate formation, and compatibility with infusion systems. A sodium chloride formulation must maintain adequate solubility without relying on an excessive excipient load.

A low-excipient formulation has several advantages:

• Fewer inactive ingredients for hospital formulary review.
• Lower risk of excipient-related intolerance.
• Simpler comparability against the reference product.
• Lower manufacturing complexity.
• More straightforward preservative-free positioning.
• Reduced risk of incompatibility with critical-care infusion equipment.

The tradeoff is that the formulation has less latitude to address precipitation, adsorption, or long-term stability. Container selection and process control therefore carry greater importance.

What excipient strategy is strongest for a commercial nicardipine product?

The strongest strategy is a preservative-free, ready-to-use sodium chloride formulation with validated stability in a flexible infusion bag and a concentration that avoids bedside dilution.

Ready-to-use presentation

A ready-to-use bag can remove several hospital handling steps:

1. Pharmacy dilution.
2. Aseptic transfer into a syringe or bag.
3. Calculation errors during concentration adjustment.
4. Additional labeling and preparation time.
5. Delays in emergency or ICU administration.

The commercial value is highest where hospitals prioritize standardized infusions and rapid availability. A ready-to-use product also creates a practical distinction from older concentrate presentations, even when the active ingredient and route are unchanged.

Concentration selection

A product can be designed around one or more standard concentrations, such as 0.1 mg/mL or 0.2 mg/mL, subject to the applicable approved labeling. The higher concentration reduces fluid volume at a given dose and can be useful for patients with fluid restrictions. The lower concentration may simplify pump programming and support broader institutional adoption.

A manufacturer should avoid creating multiple concentrations without a clear clinical or operational reason. Each additional strength increases:

• Stability studies.
• Labeling complexity.
• Inventory requirements.
• Risk of look-alike or concentration-selection errors.
• Manufacturing and packaging costs.

The most defensible portfolio is usually one primary concentration with a second concentration reserved for a defined hospital need.

pH and chemical stability

The development program should establish:

• Assay stability over the proposed shelf life.
• Degradation products under accelerated and real-time conditions.
• pH drift.
• Color and clarity.
• Subvisible and visible particles.
• Compatibility with common infusion sets and pumps.
• Stability after opening or line connection.
• Stability under temperature excursions.
• Compatibility with common co-infused drugs where clinically relevant.

Nicardipine is particularly sensitive to formulation and delivery conditions because the product is administered continuously and often through high-use ICU equipment. The manufacturer should generate data in the final container, not only in glass laboratory vessels.

What formulations are protected by patents?

Nicardipine hydrochloride itself is not a new chemical entity. The original compound, oral products, and early intravenous products have been commercially available for decades. Core composition-of-matter and early formulation exclusivity have therefore expired.

The relevant intellectual-property question is not whether nicardipine is patented as a molecule. It is whether a manufacturer has active rights covering a specific ready-to-use sodium chloride formulation, concentration, container, manufacturing process, or method of use.

Potential claim categories include:

Claim category	Relevance to nicardipine sodium chloride
Composition of matter	Low relevance; historical rights have expired
Simple sodium chloride formulation	Likely limited patent value unless a non-obvious stability or concentration feature exists
Ready-to-use bag	Possible protection for a specific concentration, container, or stability profile
pH-controlled formulation	Possible, but patent strength depends on unexpected technical effects
Container-closure system	Potential protection for adsorption, permeability, or shelf-life performance
Manufacturing process	Possible protection for sterile filtration, filling, nitrogen control, or impurity reduction
Method of use	Possible only for specific patient populations, dosing regimens, or clinical settings
Device or infusion system	Potentially separate from drug-product rights

A generic manufacturer should distinguish between patentability and freedom to operate. A formulation may be patentable, but a narrow claim may have limited commercial blocking power. Conversely, a process or container patent can create launch friction even when the product composition is simple.

What is the Orange Book status of nicardipine hydrochloride injection?

The FDA Orange Book identifies approved drug products and any listed patents or regulatory exclusivities associated with approved applications. Because nicardipine hydrochloride injection is an old small-molecule product, the central regulatory pathway for new entrants is generally an abbreviated new drug application rather than a new-drug application relying on novel active-ingredient exclusivity. [3]

The commercial analysis should separate three issues:

1. Whether the reference product has an active Orange Book patent listing.
2. Whether a proposed generic has a therapeutically equivalent listing.
3. Whether a specific premixed sodium chloride presentation is already covered by an approved ANDA.

An applicant filing an ANDA must address listed patents through the applicable certification. If a Paragraph IV certification is submitted, the patent holder may file infringement litigation within the statutory period, potentially triggering a 30-month stay under the Hatch-Waxman framework. [4]

For an old nicardipine injection product, Paragraph IV risk is more likely to involve a later presentation or formulation patent than the active ingredient itself. No biosimilar pathway applies because nicardipine is a chemically synthesized small molecule.

When does nicardipine hydrochloride lose exclusivity?

Nicardipine lost practical molecule-level exclusivity many years ago. The relevant launch question is therefore product-specific, not molecule-specific.

Exclusivity type	Position for nicardipine sodium chloride
New chemical entity exclusivity	Expired
Orphan-drug exclusivity	Not a central feature of the product
Pediatric exclusivity	No current strategic significance
Composition-of-matter patent	Historical rights expired
Formulation patent	Must be checked against current Orange Book and patent records
Method-of-use patent	Must be assessed claim by claim
Generic competition	Established or expected for conventional injection products

A manufacturer cannot assume that the absence of molecule patents eliminates all launch risk. A specific ready-to-use presentation can have separate regulatory or contractual barriers, including application-specific patents, supply agreements, manufacturing qualification requirements, and hospital conversion costs.

Are there Paragraph IV challenges to nicardipine sodium chloride products?

Paragraph IV activity depends on currently listed patents for the relevant reference product and presentation. The primary risk arises when a generic applicant seeks approval for a product that differs from an established concentrate or premix in concentration, diluent, container, or shelf-life profile.

A Paragraph IV strategy could target:

• A listed formulation patent.
• A method-of-use patent.
• A container or delivery-system patent.
• A later-issued patent covering an improved premix.
• A patent claiming a specific stability window or impurity profile.

The practical value of a Paragraph IV challenge depends on claim breadth, patent term, product sales, and the probability that the patent can be designed around. For an old injectable drug with modest annual sales, litigation economics may favor a design-around or first-to-file settlement rather than prolonged litigation.

No specific current Paragraph IV litigation should be inferred without matching the relevant patent number to the applicable FDA-listed product and court docket. FDA Orange Book records and PACER or district-court filings are the controlling sources. [3,5]

What patent litigation affects nicardipine hydrochloride injection?

The principal litigation risk is likely to be formulation-specific rather than molecule-specific. Relevant disputes would involve:

• Infringement by a premixed sodium chloride formulation.
• Validity of claims covering concentration or pH.
• Infringement by a flexible bag or container-closure system.
• Stability or manufacturing-process claims.
• Use of the product in a defined ICU or perioperative setting.

A strong patent estate would need claims that connect the formulation feature to an unexpected technical result. Generic claims covering nicardipine in ordinary sodium chloride are vulnerable to anticipation, obviousness, and lack of written-description challenges, particularly where the vehicle and active ingredient are conventional.

How strong is the patent estate for nicardipine in sodium chloride?

The underlying patent estate is likely weak at the active-ingredient level and potentially moderate only for narrowly defined product improvements.

Factors supporting a weak estate

• Long commercial history.
• Expired chemical patents.
• Conventional active pharmaceutical ingredient.
• Conventional sodium chloride vehicle.
• Limited excipient complexity.
• Established clinical use and infusion technology.

Factors that can support a stronger improvement patent

• Demonstrated stability advantage over existing products.
• Reduced adsorption to infusion equipment.
• Improved compatibility with common bags or tubing.
• A concentration that solves a documented clinical problem.
• Lower particulate burden or degradation.
• A manufacturing process that materially reduces impurities.
• A defined shelf life under challenging storage conditions.

A formulation patent should be tested against prior art involving nicardipine concentrates, diluted infusion solutions, calcium-channel blocker injections, flexible infusion bags, and acidic aqueous formulations. Broad claims are unlikely to provide durable exclusion unless supported by robust comparative data.

What commercial opportunities exist for nicardipine sodium chloride?

Ready-to-use hospital products

The clearest opportunity is a premixed sodium chloride bag that can move directly from pharmacy inventory to the infusion pump. Hospitals may value reduced preparation time, fewer compounding steps, and lower medication-error exposure.

Shortage-resilient supply

Injectable products are vulnerable to manufacturing interruptions, sterilization failures, raw-material constraints, and container shortages. A second qualified supplier with validated bag manufacturing can capture contracts even without patent differentiation.

Flexible-bag and small-volume options

Potential commercial presentations include:

• Standard-volume bags for routine ICU use.
• Higher-concentration bags for fluid-restricted patients.
• Smaller-volume bags for operating rooms or emergency departments.
• Pharmacy-ready cartons with barcode and unit-dose labeling.
• Presentations compatible with automated dispensing and inventory systems.

Contract manufacturing and licensing

Nicardipine offers a potential licensing platform for manufacturers with:

• Sterile liquid filling capacity.
• Flexible-bag technology.
• Injectable product development expertise.
• Existing hospital contracts.
• FDA-approved facilities with available capacity.

Licensing value is likely to depend more on manufacturing readiness, approved status, supply history, and distribution reach than on a broad patent portfolio. No material licensing transaction should be assumed without a documented agreement involving the relevant product, applicant, or patent holder.

503B outsourcing

A 503B outsourcing facility may prepare nicardipine infusions for hospitals under applicable FDA requirements, but outsourcing does not provide the same market position as an FDA-approved commercial product. A 503B strategy carries different rules for bulk substances, compounding, labeling, quality systems, and distribution. [6]

How does nicardipine compare with competing intravenous antihypertensives?

Product	Main advantage	Main commercial distinction
Nicardipine injection	Titrated arterial vasodilation and established ICU use	Premix convenience and supply reliability
Clevidipine emulsion	Very rapid titration and short half-life	Lipid-emulsion handling, cost, and different formulation requirements
Labetalol injection	Combined alpha and beta blockade	Different contraindications and bolus/infusion use
Esmolol injection	Short-acting beta blockade	Primarily heart-rate and sympathetic-control applications
Sodium nitroprusside	Potent vasodilation	Toxicology, monitoring, and light-protection considerations
Hydralazine injection	Intermittent arterial vasodilation	Less predictable titration in some settings

Nicardipine’s competitive position is strongest when clinicians need predictable titration without the formulation complexity of a lipid emulsion. Clevidipine is the closest premium competitor in rapid ICU blood-pressure control, while labetalol competes where beta-blockade is clinically appropriate.

What FDA regulatory strategy is available for a new manufacturer?

A conventional equivalent product would generally pursue an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant would need to establish pharmaceutical equivalence, bioequivalence where applicable, sterility, stability, container-closure suitability, and manufacturing controls. [7]

A 505(b)(2) application may be considered where the product has a material difference from the reference product, such as:

• A novel ready-to-use presentation.
• A new concentration.
• A distinct container system.
• A different diluent or formulation.
• Clinical or usability data supporting a modified product.

For an injectable product, the main regulatory risks are usually manufacturing and product-quality risks rather than clinical efficacy risks. FDA review will focus heavily on sterility assurance, endotoxins, particulate matter, extractables and leachables, container integrity, pH, assay, impurities, and in-use stability.

What generic launch risks exist for nicardipine sodium chloride?

The main launch risks are operational:

• Failure to demonstrate adequate shelf life in the final bag.
• Incompatibility with infusion tubing or pumps.
• Low hospital demand relative to minimum efficient batch size.
• Manufacturing-site qualification delays.
• Shortage of suitable flexible bags.
• Concentration confusion with existing products.
• Hospital reluctance to convert from an established concentrate.
• Price erosion after multiple ANDA approvals.
• Difficulty maintaining reliable supply of sterile injectable product.

Because the molecule is mature, a new entrant needs a defensible commercial reason for adoption. The most credible reasons are ready-to-use convenience, lower total preparation cost, reliable supply, a useful concentration, and verified compatibility.

Key Takeaways

• Nicardipine hydrochloride in sodium chloride is a mature injectable product with no meaningful molecule-level exclusivity.
• The commercial opportunity lies in premixed, preservative-free, ready-to-use infusion bags.
• Sodium chloride is a simple vehicle, but pH, stability, particulate control, and container compatibility are critical.
• Product-specific formulation or container patents may exist even though the active ingredient is long off-patent.
• Paragraph IV risk should be assessed against current Orange Book listings, not against historical nicardipine patents.
• An ANDA is generally the principal pathway for an equivalent product; a 505(b)(2) route may apply to a materially differentiated presentation.
• The strongest commercial differentiators are supply reliability, hospital workflow, concentration choice, and manufacturing quality.
• Nicardipine competes most directly with clevidipine, labetalol, esmolol, and other titratable intravenous antihypertensives.
• No biosimilar risk applies because nicardipine is a small-molecule drug.
• Patent value is likely to be concentrated in narrow formulation, packaging, stability, or manufacturing claims.

FAQs About Nicardipine Hydrochloride in Sodium Chloride

Is sodium chloride the only meaningful excipient in a nicardipine premix?

It is usually the principal vehicle and tonicity agent. Hydrochloric acid or sodium hydroxide may be used for pH adjustment, and Water for Injection is the solvent. Exact inactive ingredients depend on the manufacturer and presentation.

Can a manufacturer patent a nicardipine ready-to-use bag?

Yes, but patentability would generally depend on a specific formulation, container, manufacturing process, stability result, or technical effect. A broad claim covering nicardipine in ordinary sodium chloride would face substantial prior-art risk.

Does nicardipine hydrochloride have biosimilar competition?

No. Biosimilars apply to biological products. Nicardipine hydrochloride is a chemically synthesized small molecule and is regulated through generic-drug pathways.

Is a premixed nicardipine product automatically substitutable for a concentrate?

No. Substitution depends on FDA approval, therapeutic-equivalence designation, labeling, concentration, dosage form, and applicable state pharmacy rules. A premix and concentrate may not be operationally interchangeable.

What is the main barrier to entering the nicardipine injection market?

Sterile manufacturing reliability is usually the largest barrier. Product development is technically manageable, but maintaining validated aseptic production, bag supply, shelf life, hospital qualification, and consistent distribution can determine commercial success.

References

1. U.S. Food and Drug Administration. (2024). Nicardipine hydrochloride injection prescribing information. DailyMed. https://dailymed.nlm.nih.gov/

2. National Library of Medicine. (2024). Nicardipine hydrochloride drug information. DailyMed. https://dailymed.nlm.nih.gov/

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Patent certifications and the 30-month stay. FDA. https://www.fda.gov/

5. U.S. Courts. (2024). PACER case locator. https://pcl.uscourts.gov/

6. U.S. Food and Drug Administration. (2024). Registered outsourcing facilities. FDA. https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities

7. U.S. Food and Drug Administration. (2024). Generic drug facts. FDA. https://www.fda.gov/drugs/generic-drugs/generic-drug-facts